Anthony El-khoueiry

Agenus to Reveal Phase 1 HCC Immunotherapy Data at AACR 2025

Agenus shared on LinkedIn:

“Stay tuned for AACR 25, where Dr. Anthony El-khoueiry will present data from our Phase 1 trial evaluating botensilimab/balstilimab in treatment-refractory hepatocellular carcinoma (HCC).
Learn more.”

Agenus

More posts featuring AACR 25 on OncoDaily.

AACR 25 Agenus Anthony El-Khoueiry cancer HCC hepatocellular carcinoma OncoDaily Oncology